Quantification of Thioguanine in DNA Using Liquid Chromatography-Tandem Mass Spectrometry for Routine Thiopurine Drug Monitoring in Patients With Pediatric Acute Lymphoblastic Leukemia
2
조회
0
다운로드
3
인용
0
참고문헌
키워드
초록
Background: We developed an assay to measure DNA-incorporated 6-thioguanine (DNA-TG) and validated its clinical applicability in Korean pediatric patients with acute lymphoblastic leukemia (ALL) in order to improve individualized thiopurine treatment and reduce the life-threatening cytotoxicity. Methods: The DNA-TG assay was developed based on liquid chromatography-tandem mass spectrometry, with isotope-labeled TG-d3 and guanine-d3 as internal standards. This method was applied to 257 samples of pediatric ALL patients. The DNA-TG level was compared with erythrocyte TG nucleotide (RBC-TGN) level in relation to the TPMT and NUDT15 genotypes, which affect thiopurine metabolism, using Spearman’s rank test and repeated measure ANOVA. Results: For DNA-TG quantification, a linearity range of 10.0-5,000.0 fmol TG/μg DNA; bias for accuracy of –10.4% –3.5%; coefficient of variation for intra- and inter-day precision of 3.4% and 5.8% at 80 fmol TG/μg DNA and of 4.9% and 5.3% at 800 fmol TG/μg DNA, respectively; and recovery of 85.7%-116.2% were achieved without matrix effects or carry-over. The median DNA-TG level in the 257 samples was 106.0 fmol TG/μg DNA (interquartile range, 75.8-150.9). There was a strong correlation between DNA-TG and RBC-TGN levels (ρ=0.68, P<0.0001). The DNA-TG/RBC-TGN ratio was significantly higher in NUDT15 intermediate metabolizers (*1/*2 and *1/*3) than in patients with wild-type alleles (P<0.0001). Conclusions: This simple and sensitive method for measuring DNA-TG level can improve therapeutic drug monitoring for thiopurine treatment.
Abstract
Background: We developed an assay to measure DNA-incorporated 6-thioguanine (DNA-TG) and validated its clinical applicability in Korean pediatric patients with acute lymphoblastic leukemia (ALL) in order to improve individualized thiopurine treatment and reduce the life-threatening cytotoxicity. Methods: The DNA-TG assay was developed based on liquid chromatography-tandem mass spectrometry, with isotope-labeled TG-d3 and guanine-d3 as internal standards. This method was applied to 257 samples of pediatric ALL patients. The DNA-TG level was compared with erythrocyte TG nucleotide (RBC-TGN) level in relation to the TPMT and NUDT15 genotypes, which affect thiopurine metabolism, using Spearman’s rank test and repeated measure ANOVA. Results: For DNA-TG quantification, a linearity range of 10.0-5,000.0 fmol TG/μg DNA; bias for accuracy of –10.4% –3.5%; coefficient of variation for intra- and inter-day precision of 3.4% and 5.8% at 80 fmol TG/μg DNA and of 4.9% and 5.3% at 800 fmol TG/μg DNA, respectively; and recovery of 85.7%-116.2% were achieved without matrix effects or carry-over. The median DNA-TG level in the 257 samples was 106.0 fmol TG/μg DNA (interquartile range, 75.8-150.9). There was a strong correlation between DNA-TG and RBC-TGN levels (ρ=0.68, P<0.0001). The DNA-TG/RBC-TGN ratio was significantly higher in NUDT15 intermediate metabolizers (*1/*2 and *1/*3) than in patients with wild-type alleles (P<0.0001). Conclusions: This simple and sensitive method for measuring DNA-TG level can improve therapeutic drug monitoring for thiopurine treatment.
참고문헌 (29)
- Coulthard SA, "Liquid chromatography-mass spectrometry for measuring deoxythioguanosine in DNA from thiopurine-treated patients", J Chromatogr B Analyt Technol Biomed Life Sci, 1028, pp.175~180 (2016)
- Moon SY, "Quantification of thiopurine nucleotides in erythrocytes and clinical application to pediatric acute lymphoblastic leukemia", Ther Drug Monit, 41, pp.75~85 (2019)
- Lampič K, "Determination of 6-thioguanine and 6-methylmercaptopurine in dried blood spots using liquid chromatography-tandem mass spectrometry: Method development, validation and clinical application", Clin Chim Acta, 499, pp.24~33 (2019)
- Moriyama T, "The effects of inherited NUDT15 polymorphisms on thiopurine active metabolites in Japanese children with acute lymphoblastic leukemia", Pharmacogenet Genomics, 27, pp.236~239 (2017)
- Moriyama T, "NUDT15 polymorphisms alter thiopurine metabolism and hematopoietic toxicity", Nat Genet, 48, pp.367~373 (2016)
- Liquid chromatography-mass spectrometry methods; approved guideline, "CLSI", Clinical and Laboratory Standards Institute, ~, pp.CLSI document C62-A (2014)
- Jacobsen JH, "Liquid chromatography-tandem mass spectrometry quantification of 6-thioguanine in DNA using endogenous guanine as internal standard", J Chromatogr B Analyt Technol Biomed Life Sci, 881-882, pp.115~118 (2012)
- "Bioanalytical method validation guidance for industry" (2018)[URL]
- Zaza G, "Thiopurine pathway", Pharmacogenet Genomics, 20, pp.573~574 (2010)
- Relling MV, "Clinical Pharmacogenetics Implementation Consortium guideline for thiopurine dosing based on TPMT and NUDT15 genotypes: 2018 update", Clin Pharmacol Ther, 105, pp.1095~1105 (2019)
- Adam de Beaumais T, "Determinants of mercaptopurine toxicity in paediatric acute lymphoblastic leukemia maintenance therapy", Br J Clin Pharmacol, 71, pp.575~584 (2011)
- Kim HY, "Complete sequence-based screening of TPMT variants in the Korean population", Pharmacogenet Genomics, 25, pp.143~146 (2015)
- Yang JJ, "Inherited NUDT15 variant is a genetic determinant of mercaptopurine intolerance in children with acute lymphoblastic leukemia", J Clin Oncol, 33, pp.1235~1242 (2015)
- Warren DJ, "Quantitation of 6-thioguanine residues in peripheral blood leukocyte DNA obtained from patients receiving 6-mercaptopurine-based maintenance therapy", Cancer Res, 55, pp.1670~1674 (1995)
- Nielsen SN, "Measures of 6-mercaptopurine and methotrexate maintenance therapy intensity in childhood acute lymphoblastic leukemia", Cancer Chemother Pharmacol, 78, pp.983~994 (2016)
- Nielsen SN, "DNA-thioguanine nucleotide concentration and relapse-free survival during maintenance therapy of childhood acute lymphoblastic leukaemia (NOPHO ALL2008): a prospective substudy of a phase 3 trial", Lancet Oncol, 18, pp.515~524 (2017)
- "Draft guideline on bioanalytical method validation in pharmaceutical development" (2013)[URL]
- "Guideline on bioanalytical method validation" (2012)[URL]
- Mass spectrometry in the clinical laboratory: general principles and guidance; approved guideline, "CLSI", PA:Clinical and Laboratory Standards Institute, ~, pp.CLSI document C50-A (2007)
- Scientific Working Group for Forensic Toxicology, "Scientific Working Group for Forensic Toxicology (SWGTOX) standard practices for method validation in forensic toxicology", J Anal Toxicol, 37, pp.452~474 (2013)
- "Guideline on bioanalytical method validation" (2013)[URL]
- Dervieux T, "Liquid chromatography-tandem mass spectrometry analysis of erythrocyte thiopurine nucleotides and effect of thiopurine methyltransferase gene variants on these metabolites in patients receiving azathioprine", 6-mercaptopurine therapy, 2005, pp.51, 2074~2084
- Lee MN, "Impact of genetic polymorphisms on 6-thioguanine nucleotide levels and toxicity in pediatric patients with IBD treated with azathioprine", Inflamm Bowel Dis, 21, pp.2897~2908 (2015)
- 유인영, "Evaluation of Stability of Thiopurine Metabolites Using a Validated LC-MS", MS Method, 2018, pp.38(3), 255~260[DOI]
- Kim HT, "NUDT15 genotype distributions in the Korean population", Pharmacogenet Genomics, 27, pp.197~200 (2017)
- Coulthard SA, "The effect of thiopurine methyltransferase expression on sensitivity to thiopurine drugs", Mol Pharmacol, 62, pp.102~109 (2002)
- Choi R, "Pathway genes and metabolites in thiopurine therapy in Korean children with acute lymphoblastic leukaemia", Br J Clin Pharmacol, 85, pp.1585~1597 (2019)
- Yang JJ, "Pharmacogene Variation Consortium gene introduction: NUDT15", Clin Pharmacol Ther, 105, pp.1091~ (2019)
- Selinger CP, "The accuracy of adherence self-report scales in patients on thiopurines for inflammatory bowel disease: a comparison with drug metabolite levels and medication possession ratios", Inflamm Bowel Dis, 25, pp.919~924 (2019)